Clinical implications of the glucokinase impaired function - GCK MODY today.

Heterozygous inactivating mutations of the glucokinase (GCK) gene are causing GCK-MODY, one of the most common forms of the Maturity Onset Diabetes of the Young (MODY). GCK-MODY is characterized by fasting hyperglycemia without apparent worsening with aging and low risk for chronic vascular complications. Despite the mild clinical course, GCK-MODY could be misdiagnosed as type 1 or type 2 diabetes. In the diagnostic process, the clinical suspicion is often based on the clinical diagnostic criteria for GCK-MODY and should be confirmed by DNA analysis. However, there are several issues in the clinical and also in genetic part that could complicate the diagnostic process. Most of the people with GCK-MODY do not require any pharmacotherapy. The exception are pregnant women with a fetus which did not inherit GCK mutation from the mother. Such a child has accelerated growth, and has increased risk for diabetic foetopathy. In this situation the mother should be treated with substitutional doses of insulin. Therefore, distinguishing GCK-MODY from gestational diabetes in pregnancy is very important. For this purpose, special clinical diagnostic criteria for clinical identification of GCK-MODY in pregnancy are used. This review updates information on GCK-MODY and discusses several currently not solved problems in the clinical diagnostic process, genetics, and treatment of this type of monogenic diabetes.

[1]  K. Clément,et al.  Primary pancreatic beta-cell secretory defect caused by mutations in glucokinase gene in kindreds of maturity onset diabetes of the young , 1992, The Lancet.

[2]  P. Iynedjian.  Mammalian glucokinase and its gene. , 1993, The Biochemical journal.

[3]  L. Agius,et al.  Intracellular binding of glucokinase in hepatocytes and translocation by glucose, fructose and insulin. , 1993, The Biochemical journal.

[4]  T. Buchanan,et al.  Use of Fetal Ultrasound to Select Metabolic Therapy for Pregnancies Complicated by Mild Gestational Diabetes , 1994, Diabetes Care.

[5]  E. Van Schaftingen,et al.  Short‐term control of glucokinase activity: role of a regulatory protein , 1994, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  K. Clément,et al.  Arginine-Induced Insulin Release in Glucokinase-Deficient Subjects , 1994, Diabetes Care.

[7]  P. Froguel,et al.  Six Mutations in the Glucokinase Gene Identified in MODY by Using a Nonradioactive Sensitive Screening Technique , 1994, Diabetes.

[8]  H. Kasai,et al.  Pancreatic beta-cell-specific targeted disruption of glucokinase gene. Diabetes mellitus due to defective insulin secretion to glucose. , 1995, The Journal of biological chemistry.

[9]  H. Kasai,et al.  Pancreatic β-Cell-specific Targeted Disruption of Glucokinase Gene , 1995, Journal of Biological Chemistry.

[10]  M. Anai,et al.  Nuclear location of the regulatory protein of glucokinase in rat liver and translocation of the regulator to the cytoplasm in response to high glucose. , 1995, Biochemical and biophysical research communications.

[11]  A. Grupe,et al.  Transgenic knockouts reveal a critical requirement for pancreatic β cell glucokinase in maintaining glucose homeostasis , 1995, Cell.

[12]  Matschinsky Fm.  Banting Lecture 1995. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm. , 1996 .

[13]  Binding and translocation of glucokinase in hepatocytes. , 1997, Biochemical Society transactions.

[14]  P. Froguel,et al.  Identification of 14 new glucokinase mutations and description of the clinical profile of 42 MODY-2 families , 1997, Diabetologia.

[15]  K. Mookhtiar,et al.  Glucokinase Regulatory Protein May Interact With Glucokinase in the Hepatocyte Nucleus , 1997, Diabetes.

[16]  M. Veiga-da-Cunha,et al.  Investigation on the mechanism by which fructose, hexitols and other compounds regulate the translocation of glucokinase in rat hepatocytes. , 1997, The Biochemical journal.

[17]  Sian Ellard,et al.  Mutations in the glucokinase gene of the fetus result in reduced birth weight , 1998, Nature Genetics.

[18]  P. Czernichow,et al.  Long-term treatment of persistent hyperinsulinaemic hypoglycaemia of infancy with diazoxide: a retrospective review of 77 cases and analysis of efficacy-predicting criteria , 1998, European Journal of Pediatrics.

[19]  M. Magnuson,et al.  Mutants of glucokinase cause hypoglycaemia- and hyperglycaemia syndromes and their analysis illuminates fundamental quantitative concepts of glucose homeostasis , 1999, Diabetologia.

[20]  J. Grippo,et al.  Nuclear Import of Hepatic Glucokinase Depends upon Glucokinase Regulatory Protein, whereas Export Is Due to a Nuclear Export Signal Sequence in Glucokinase* , 1999, The Journal of Biological Chemistry.

[21]  E. Guenat,et al.  Counterregulatory responses to hypoglycemia in patients with glucokinase gene mutations. , 2000, Diabetes & metabolism.

[22]  A. Hattersley,et al.  Maternal diabetes alters birth weight in glucokinase-deficient (MODY2) kindred but has no influence on adult weight, height, insulin secretion or insulin sensitivity , 2000, Diabetologia.

[23]  Glucokinase gene mutations are not a common cause of permanent neonatal diabetes in France , 2002, Diabetologia.

[24]  A. Hattersley,et al.  Influence of maternal and fetal glucokinase mutations in gestational diabetes. , 2001, American journal of obstetrics and gynecology.

[25]  T. Buchanan,et al.  A randomized controlled trial using glycemic plus fetal ultrasound parameters versus glycemic parameters to determine insulin therapy in gestational diabetes with fasting hyperglycemia. , 2001, Diabetes care.

[26]  S. Ellard,et al.  Complete glucokinase deficiency is not a common cause of permanent neonatal diabetes , 2002, Diabetologia.

[27]  R. Lorini,et al.  High prevalence of glucokinase mutations in Italian children with MODY. Influence on glucose tolerance, first-phase insulin response, insulin sensitivity and BMI , 2001, Diabetologia.

[28]  T. Hansen,et al.  The genetic abnormality in the beta cell determines the response to an oral glucose load , 2002, Diabetologia.

[29]  E. Guenat,et al.  Counterregulatory responses to hypoglycemia in patients with maturity-onset diabetes of the young caused by HNF-1alpha gene mutations (MODY3). , 2001, European journal of endocrinology.

[30]  F. Matschinsky.  Regulation of Pancreatic β-Cell Glucokinase: From Basics to Therapeutics , 2002 .

[31]  F. Matschinsky.  Regulation of pancreatic beta-cell glucokinase: from basics to therapeutics. , 2002, Diabetes.

[32]  A. Hattersley,et al.  Insights into the biochemical and genetic basis of glucokinase activation from naturally occurring hypoglycemia mutations. , 2003, Diabetes.

[33]  Teruyuki Nishimura,et al.  Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase. , 2004, Structure.

[34]  F. Ashcroft.  ATP-sensitive potassium channelopathies: focus on insulin secretion. , 2005, The Journal of clinical investigation.

[35]  A. Hattersley,et al.  Mutations in KCNJ11, which encodes Kir6.2, are a common cause of diabetes diagnosed in the first 6 months of life, with the phenotype determined by genotype , 2006, Diabetologia.

[36]  Shaoxian Sun,et al.  Biochemical Basis of Glucokinase Activation and the Regulation by Glucokinase Regulatory Protein in Naturally Occurring Mutations* , 2006, Journal of Biological Chemistry.

[37]  M. Magnuson,et al.  The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. , 2006, Diabetes.

[38]  T. Hansen,et al.  Aetiological heterogeneity of asymptomatic hyperglycaemia in children and adolescents , 2006, European Journal of Pediatrics.

[39]  The long-term impact on offspring of exposure to hyperglycaemia in utero due to maternal glucokinase gene mutations , 2007, Diabetologia.

[40]  S. Ellard,et al.  Heterogeneity in disease severity in a family with a novel G68V GCK activating mutation causing persistent hyperinsulinaemic hypoglycaemia of infancy , 2007, Diabetic medicine : a journal of the British Diabetic Association.

[41]  A. Hattersley,et al.  Prevalence of permanent neonatal diabetes in Slovakia and successful replacement of insulin with sulfonylurea therapy in KCNJ11 and ABCC8 mutation carriers. , 2007, The Journal of clinical endocrinology and metabolism.

[42]  T. Hansen,et al.  Partial and whole gene deletion mutations of the GCK and HNF1A genes in maturity-onset diabetes of the young , 2007, Diabetologia.

[43]  J. Argente,et al.  Permanent neonatal diabetes caused by a homozygous nonsense mutation in the glucokinase gene , 2008, Pediatric diabetes.

[44]  S. Ellard,et al.  Activating glucokinase (GCK) mutations as a cause of medically responsive congenital hyperinsulinism: prevalence in children and characterisation of a novel GCK mutation. , 2008, European journal of endocrinology.

[45]  J. Holst,et al.  Glucokinase, the pancreatic glucose sensor, is not the gut glucose sensor , 2008, Diabetologia.

[46]  P. Iynedjian.  Molecular Physiology of Mammalian Glucokinase , 2008, Cellular and Molecular Life Sciences.

[47]  R. Holman,et al.  Prevalence of GCK mutations in individuals screened for fasting hyperglycaemia , 2008, Diabetologia.

[48]  A. Molven,et al.  Diagnostic screening of MODY2/GCK mutations in the Norwegian MODY Registry , 2008, Pediatric diabetes.

[49]  S. Ellard,et al.  Permanent neonatal diabetes mellitus caused by a novel homozygous (T168A) glucokinase (GCK) mutation: initial response to oral sulphonylurea therapy. , 2008, The Journal of pediatrics.

[50]  S. Ellard,et al.  Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young , 2008, Diabetologia.

[51]  C. Stanley,et al.  Extremes of Clinical and Enzymatic Phenotypes in Children With Hyperinsulinism Caused by Glucokinase Activating Mutations , 2009, Diabetes.

[52]  G. d’Annunzio,et al.  Maturity-Onset Diabetes of the Young in Children With Incidental Hyperglycemia: , 2009, Diabetes Care.

[53]  S. Ellard,et al.  Update on mutations in glucokinase (GCK), which cause maturity‐onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia , 2009, Human mutation.

[54]  A. Hattersley,et al.  Pregnancy outcome in patients with raised blood glucose due to a heterozygous glucokinase gene mutation , 2009, Diabetic medicine : a journal of the British Diabetic Association.

[55]  A. Hattersley,et al.  The diagnosis and management of monogenic diabetes in children and adolescents , 2009, Pediatric diabetes.

[56]  J. Knight,et al.  Identification of a Novel β-Cell Glucokinase (GCK) Promoter Mutation (−71G>C) That Modulates GCK Gene Expression Through Loss of Allele-Specific Sp1 Binding Causing Mild Fasting Hyperglycemia in Humans , 2009, Diabetes.

[57]  E. Mayatepek,et al.  Diagnostic difficulties in glucokinase hyperinsulinism. , 2009, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[58]  M. McCarthy,et al.  Evaluation of Serum 1,5 Anhydroglucitol Levels as a Clinical Test to Differentiate Subtypes of Diabetes , 2010, Diabetes Care.

[59]  Bengt Persson,et al.  International Association of Diabetes and Pregnancy Study Groups Recommendations on the Diagnosis and Classification of Hyperglycemia in Pregnancy , 2010, Diabetes Care.

[60]  B. Shields,et al.  Maturity-onset diabetes of the young (MODY): how many cases are we missing? , 2010, Diabetologia.

[61]  A. Dyer,et al.  International Association of Diabetes and Pregnancy Study Groups Recommendations on the Diagnosis and Classification of Hyperglycemia in Pregnancy , 2010, Diabetes Care.

[62]  M. McCarthy,et al.  Assessment of High-Sensitivity C-Reactive Protein Levels as Diagnostic Discriminator of Maturity-Onset Diabetes of the Young Due to HNF1A Mutations , 2010, Diabetes Care.

[63]  A De Novo Whole GCK Gene Deletion Not Detected by Gene Sequencing, in a Boy with Phenotypic GCK Insufficiency , 2011, Case reports in genetics.

[64]  T. Klupa,et al.  Permanent neonatal diabetes mellitus – the importance of diabetes differential diagnosis in neonates and infants , 2011, European journal of clinical investigation.

[65]  B. Shields,et al.  The development and validation of a clinical prediction model to determine the probability of MODY in patients with young-onset diabetes , 2012, Diabetologia.

[66]  B. Shields,et al.  Urine C-Peptide Creatinine Ratio Is a Noninvasive Alternative to the Mixed-Meal Tolerance Test in Children and Adults With Type 1 Diabetes , 2011, Diabetes Care.

[67]  P. Bingley,et al.  Islet autoantibodies can discriminate maturity‐onset diabetes of the young (MODY) from Type 1 diabetes , 2011, Diabetic medicine : a journal of the British Diabetic Association.

[68]  B. Shields,et al.  High-Sensitivity CRP Discriminates HNF1A-MODY From Other Subtypes of Diabetes , 2011, Diabetes Care.

[69]  L. Pianese,et al.  A new de novo mutation in the GCK gene causing MODY2. , 2011, Diabetes research and clinical practice.

[70]  Impact of Type 2 diabetes on Glucokinase diabetes (GCK-MODY) phenotype in a Roma (Gypsy) family - case report. , 2012, Endocrine regulations.

[71]  To test, or not to test: time for a MODY calculator? , 2012, Diabetologia.

[72]  Nicola L. Beer,et al.  Identification and Functional Characterisation of Novel Glucokinase Mutations Causing Maturity-Onset Diabetes of the Young in Slovakia , 2012, PloS one.

[73]  M. Evans,et al.  Brain Glucose Sensors Play a Significant Role in the Regulation of Pancreatic Glucose-Stimulated Insulin Secretion , 2012, Diabetes.

[74]  M. Skopkova,et al.  De novo mutations of GCK, HNF1A and HNF4A may be more frequent in MODY than previously assumed , 2014, Diabetologia.

[75]  B. Shields,et al.  Cross-sectional and longitudinal studies suggest pharmacological treatment used in patients with glucokinase mutations does not alter glycaemia , 2013, Diabetologia.

[76]  B. Shields,et al.  Use of HbA1c in the Identification of Patients with Hyperglycaemia Caused by a Glucokinase Mutation: Observational Case Control Studies , 2013, PloS one.

[77]  B. Shields,et al.  Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia. , 2014, JAMA.

[78]  A. Hattersley,et al.  The 0.1% of the Population With Glucokinase Monogenic Diabetes Can Be Recognized by Clinical Characteristics in Pregnancy: The Atlantic Diabetes in Pregnancy Cohort , 2014, Diabetes Care.

[79]  A. Hattersley,et al.  The diagnosis and management of monogenic diabetes in children and adolescents , 2014 .

[80]  B. Bendlova,et al.  Gestational diabetes - metabolic risks of adult women with respect to birth weight. , 2015, Physiological research.

[81]  B. Shields,et al.  Recognition and Management of Individuals With Hyperglycemia Because of a Heterozygous Glucokinase Mutation , 2015, Diabetes Care.

[82]  Marcus J Hinchcliffe,et al.  Identifying Glucokinase Monogenic Diabetes in a Multiethnic Gestational Diabetes Mellitus Cohort: New Pregnancy Screening Criteria and Utility of HbA1c , 2015, Diabetes Care.

[83]  S. Ellard,et al.  GCK gene mutations are a common cause of childhood‐onset MODY (maturity‐onset diabetes of the young) in Turkey , 2016, Clinical endocrinology.

[84]  S. Bloom,et al.  Insights into the role of neuronal glucokinase , 2016, American journal of physiology. Endocrinology and metabolism.

[85]  L. Enquist,et al.  The Brain–to–Pancreatic Islet Neuronal Map Reveals Differential Glucose Regulation From Distinct Hypothalamic Regions , 2016, Diabetes.

[86]  A. Hattersley,et al.  Analysis of cell‐free fetal DNA for non‐invasive prenatal diagnosis in a family with neonatal diabetes , 2016, Diabetic medicine : a journal of the British Diabetic Association.

[87]  M. Skopkova,et al.  Congenital hyperinsulinism and glycogenosis-like phenotype due to a novel HNF4A mutation. , 2017, Diabetes research and clinical practice.

[88]  Hypothalamic arcuate glucokinase and its downstream pathways are critical in glucose homeostasis , 2018, Endocrine Abstracts.

[89]  Neonatal hypoglycemia, early-onset diabetes and hypopituitarism due to the mutation in EIF2S3 gene causing MEHMO syndrome. , 2018 .

[90]  G. Rutter,et al.  Hypothalamic arcuate nucleus glucokinase regulates insulin secretion and glucose homeostasis , 2018, Diabetes, obesity and metabolism.

[91]  A. Hattersley,et al.  ISPAD Clinical Practice Consensus Guidelines 2018: The diagnosis and management of monogenic diabetes in children and adolescents , 2018, Pediatric diabetes.

[92]  P. Rorsman,et al.  α-cell glucokinase suppresses glucose-regulated glucagon secretion , 2018, Nature Communications.

[93]  David F Wilson,et al.  The Central Role of Glucokinase in Glucose Homeostasis: A Perspective 50 Years After Demonstrating the Presence of the Enzyme in Islets of Langerhans , 2019, Front. Physiol..

[94]  B. Miller,et al.  Molecular and cellular regulation of human glucokinase. , 2019, Archives of biochemistry and biophysics.

[95]  K. Hussain,et al.  The Genetic and Molecular Mechanisms of Congenital Hyperinsulinism , 2019, Front. Endocrinol..

[96]  M. Haluzík,et al.  Insulin-like growth factor axis in pregnancy and gestational diabetes mellitus. , 2019, Physiological research.

[97]  Catarina I. Gonçalves,et al.  Maturity-Onset Diabetes of the Young (MODY) in Portugal: Novel GCK, HNFA1 and HNFA4 Mutations , 2020, Journal of clinical medicine.